Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.
Saved in:
| Title: | Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. |
|---|---|
| Authors: | Chen Y; Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong-An Road, Shanghai, 200032, China., Dai S; Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong-An Road, Shanghai, 200032, China., Cheng CS; Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. natcheng@connect.hku.hk.; Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong-An Road, Shanghai, 200032, China. natcheng@connect.hku.hk., Chen L; Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China. lianyu-chen@alu.fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong-An Road, Shanghai, 200032, China. lianyu-chen@alu.fudan.edu.cn. |
| Source: | Journal of hematology & oncology [J Hematol Oncol] 2024 Dec 21; Vol. 17 (1), pp. 130. Date of Electronic Publication: 2024 Dec 21. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
